Characteristics and outcomes in sero-positive late-onset rheumatoid arthritis patients who start a new disease modifying anti-rheumatic drug

被引：0
|
作者：
Ranganath, V. K. [1 ]
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
ARTHRITIS RESEARCH & THERAPY | 2005年 / 7卷
关键词：
Rheumatoid Arthritis; Rheumatoid Arthritis Patient; Propensity Score; Rheumatoid Factor; Generalize Match;
D O I：
10.1186/ar1687
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [1] Characteristics and outcomes in sero-positive late-onset rheumatoid arthritis patients who start a new disease modifying anti-rheumatic drug
    VK Ranganath
    Arthritis Research & Therapy, 7
  • [2] Completer analysis comparing younger and older onset sero-positive early rheumatoid arthritis patients who needed a new disease modifying anti-rheumatic drug.
    Ranganath, Veena K.
    Furst, Daniel E.
    Elashoff, David A.
    Xu, Feng
    Chon, Yuri
    Jawaheer, Damini
    Louie, James
    Hahn, Theodore
    Paulus, Harold H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S386 - S386
  • [3] DISEASE MODIFYING ANTI-RHEUMATIC DRUG ADHERENCE IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS
    Ayano, Nakayama
    Bruce, Shadbolt
    Allison, Tong
    Kathleen, Tymms
    Chandima, Perera
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 17 - 17
  • [4] Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
    Hameed, M.
    Exarchou, S.
    Eberhard, A.
    Sharma, A.
    Bergstrom, U.
    Einarsson, J.
    Turesson, C.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 : 67 - 68
  • [5] Predictors at Diagnosis for Start of Biologic Disease Modifying Anti-Rheumatic Drugs in Patients with Early Rheumatoid Arthritis
    Hameed, Mohaned
    Exarchou, Sofia
    Eberhard, Anna
    Sharma, Ankita
    Bergstrom, Ulf
    Einarsson, Jon
    Turesson, Carl
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2831 - 2833
  • [6] Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review
    Giollo, Alessandro
    Bissell, Lesley-Anne
    Buch, Maya H.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (07) : 697 - 708
  • [7] Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story
    Smolen, JS
    Graninger, WB
    Emery, P
    RHEUMATOLOGY, 2000, 39 (07) : 689 - 692
  • [8] Is cholecalciferol a potential disease-modifying anti-rheumatic drug for the management of rheumatoid arthritis?
    Bellan, M.
    Andreoli, L.
    Nerviani, A.
    Piantoni, S.
    Avanzi, G. C.
    Soddu, D.
    Hayden, E.
    Pirisi, M.
    Sainaghi, P. P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (02) : 343 - 349
  • [9] Effectiveness of disease modifying anti-rheumatic drug risk communication in rheumatoid arthritis.
    Martin, Richard W.
    McIntosh, Barbara A.
    Swartz, Timothy J.
    Head, Andrew J.
    Fiechtner, Justus J.
    Rene, Jonathan
    Holmes-Rovner, Margaret
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S369 - S369
  • [10] Time to Disease-Modifying Anti-Rheumatic Drug Treatment for New Patients with Rheumatoid Arthritis - Single Center Experience
    Jese, Rok
    Ambrozic, Ales
    Gaspersic, Natasa
    Hocevar, Alojzija
    Lestan, Boris
    Novljan, Martina Plesivcnik
    Praprotnik, Sonja
    Rotar, Ziga
    Dolnicar, Alenka Sipek
    Tomsic, Matija
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
12345